Understanding the Current Rating
MarketsMOJO’s 'Sell' rating for Pfizer Ltd. is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. This rating suggests that investors should exercise caution with the stock, as the current outlook indicates challenges that may affect returns in the near to medium term. The rating was adjusted on 29 December 2025, reflecting a significant change in the company’s mojo score, which dropped by 17 points from 54 to 37, signalling a shift in the stock’s overall attractiveness.
Quality Assessment
As of 02 June 2026, Pfizer Ltd. maintains a good quality grade. This indicates that the company has a solid operational foundation and a respectable return on equity (ROE) of 18.1%. Such a ROE suggests that Pfizer is generating reasonable profits relative to shareholder equity, which is a positive sign for long-term investors. However, the company’s growth trajectory has been modest, with net sales increasing at an annual rate of just 2.39% over the past five years, and operating profit growing at 7.03% annually. These figures point to a stable but slow expansion, which may not be sufficient to excite growth-focused investors.
Valuation Considerations
Valuation is a critical factor in the current rating, with Pfizer Ltd. classified as very expensive at present. The stock trades at a price-to-book (P/B) ratio of 4.9, which is high compared to typical benchmarks and indicates that investors are paying a premium for the company’s assets. While the stock’s valuation is in line with its peers’ historical averages, the premium suggests expectations of strong future performance that may not be fully supported by current fundamentals. Despite this, Pfizer offers a relatively attractive dividend yield of 3.7%, which provides some income cushion for investors amid valuation concerns.
Financial Trend Analysis
The financial trend for Pfizer Ltd. is currently flat, reflecting a lack of significant momentum in recent quarters. The latest results for March 2026 showed little change, indicating that the company is not experiencing either strong growth or decline at this time. Over the past year, the stock has delivered a negative return of approximately -20.04%, underperforming broader market indices such as the BSE500. Interestingly, while the stock price has declined, the company’s profits have risen by 19.8% over the same period, resulting in a PEG ratio of 1.4. This disparity suggests that the market may be cautious about the sustainability of profit growth or other external factors impacting investor sentiment.
Technical Outlook
From a technical perspective, Pfizer Ltd. is currently rated bearish. The stock has experienced consistent downward pressure, with recent price movements showing declines of -0.05% on the day, -3.07% over the past week, and -9.74% over six months. This negative momentum is a warning sign for traders and investors relying on technical indicators, as it suggests continued weakness in the near term. The stock’s underperformance relative to the BSE500 over one year and three months further reinforces this cautious stance.
What This Means for Investors
For investors, the 'Sell' rating on Pfizer Ltd. implies that the stock may not currently offer favourable risk-reward dynamics. The combination of a high valuation, flat financial trends, and bearish technical signals suggests limited upside potential and a higher likelihood of price declines or stagnation. While the company’s quality metrics remain decent and the dividend yield is attractive, these positives are outweighed by concerns over growth prospects and market sentiment. Investors should carefully consider these factors in the context of their portfolio objectives and risk tolerance before initiating or maintaining positions in Pfizer Ltd.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Pfizer Ltd. faces competitive pressures and regulatory challenges that can impact its performance. The sector often demands innovation and robust pipeline development to sustain growth, and Pfizer’s modest sales growth over five years may reflect these industry dynamics. Additionally, the stock’s small-cap status may contribute to higher volatility and sensitivity to market fluctuations compared to larger peers.
Summary of Key Metrics as of 02 June 2026
- Mojo Score: 37.0 (Sell Grade)
- Market Capitalisation: Small Cap
- Return on Equity (ROE): 18.1%
- Price to Book Value: 4.9 (Very Expensive)
- Dividend Yield: 3.7%
- Annual Net Sales Growth (5 years): 2.39%
- Annual Operating Profit Growth (5 years): 7.03%
- Stock Returns: 1 Year -20.04%, 6 Months -9.74%, 3 Months -8.48%
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Investor Takeaway
In conclusion, Pfizer Ltd.’s current 'Sell' rating by MarketsMOJO reflects a cautious stance grounded in valuation concerns, subdued financial momentum, and negative technical trends. While the company’s quality remains good and dividend yield attractive, the overall outlook suggests limited near-term upside. Investors should weigh these factors carefully and monitor any changes in the company’s fundamentals or market conditions that could alter its investment appeal.
Looking Ahead
Given the pharmaceutical sector’s evolving landscape, Pfizer’s future performance will depend on its ability to innovate, manage costs, and navigate regulatory environments effectively. Monitoring quarterly results and sector developments will be crucial for investors seeking to reassess the stock’s potential. Until then, the current rating advises prudence and consideration of alternative opportunities with stronger growth and technical profiles.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
